Effect Of Infliximab Combinated With Methylprednisolone On Expression Of Bcl-2, Survivin In A Rat Model Of Acute Spinal Cord Injury

Objective:By the modified Allen's weight drop method, a model of acute spinal cord injury(ASCI) in rats was framed. Observation of infliximab, methylprednisolone and infliximab combined methylpredni-solone on acute spinal cord injury therapy, analyzed of Infliximab, methylprednisolone and infliximab combined methylprednisolone impact on Bcl-2, Survivin, expression of injured spinal cord tissues. To investigate the protective effect and possible mechanism of infliximab combined methylprednisolone.Materials and methods:90 adult Sprague Dawley rats with 300-350g body weight(BWT)were randomly divided into six primay groups:(1)Normal control group (group NC n=15);(2)Sham operation group (group SO n=15);(3) Placebo group (group NS n=15);(4) Methylprednisolone treated group(group MP N=15);(5) Infliximab treated group(group IN n=15);(6) infliximab combined methylprednisolone treated group(group IM n=15).Excepted non-surgical and non-treatment in group NC,only cut lamina in group SO,other groups were established ASCI model, and appropriate drug treated.(Methylprednisolone 30mg/kg, intraperitoneal injection; infliximab 5mg/kg, intraperitoneally; monotherapy group administered once, twice administration of drug combination therapy).Allen's weight drop method was used to establish the acute spinal cord injury (ASCI)rat model at T10 section.The appropriate drug treatment given at once, after the model was established.Group NS given normal saline 2ml by intraperitoneal injection, Group MP given methylprednisolone once (30mg/kg, intraperitoneal injection, injecting a dose of 2ml),Group IN given infliximab once (5mg/kg, intraperitoneal injection, injecting a dose of 2ml),Group IM given methylprednisolone infliximab and methylpred-nisolone(infliximab 5mg/kg, methylprednisolone 30mg/kg, intraperitoneal injection, divided doses).Group NC not to processing. Group SO given by intraperitoneal injection of nonnal saline lml in corresponding time.5 rats in each group were evaluton by BBB(Basso,Beattie, Bresnahan) locomotor rating, the remaining rats were killed 24h after spinal cord injury and spinal cord specimens were obtained. Detection indicators include:1 By immunohistochemical analysis Bcl-2, survivin expression; 2 By RT-PCR analysis Bcl-2 mRNA,survivin mRNA expression.Result:1 After injury 14d,21d, the BBB scores of rats in the group MP and the group IN were greater than the group NS (p<0.05), while MP combined Infliximab treatment group rats BBB score is greater than MP or Infliximab monotherapy groups (p<0.05). After injury 24h, MP or Infliximab treatment group treated group greater than placebo group in the expression of Bcl-2 and Survivin (p<0.05), while MP combined Infliximab treatment group was greater than MP or Infliximab monotherapy group in the expression of Bcl-2 and Survivin (p<0.05) After injury 24h, MP or Infliximab treatment group treated group greater than placebo group in the expression of Bcl-2 mRNA and Survivin mRNA (p<0.05), while MP combined Infliximab treatment group was greater than MP or Infliximab monotherapy group in the expression of Bcl-2 mRNA and Survivin mRNA (p<0.05)Conclusions:(1) infliximab, methylprednisolone on spinal cord injury has therapeutic effect, combined them with better effect. (2) infliximab, methylprednisolone can be through the promotion of anti-apoptotic protein Bcl-2, Survivin expression and reduce the degree of spinal cord injury to improve neurological function after spinal cord injury.